SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019, at 10:20 a.m. EDT (7:20...
Category: News
Melinta Therapeutics Announces Rescheduling of Second Quarter 2019 Financial Results Reporting
~ Second Quarter 2019 Financial Results to be Reported on Friday, August 9, 2019 ~ ~ Company Cancels Previously Scheduled Earnings Call ~ MORRISTOWN, N.J., Aug. 06, 2019 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced...
Entasis Therapeutics to Present at the Wedbush PacGrow Healthcare Conference
WALTHAM, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present at the 2019 Wedbush PacGrow Healthcare Conference being held August 13-14,...
VenatoRx Pharmaceuticals named ‘Best Places to Work’ Second Year in a Row
MALVERN, Pa.–(BUSINESS WIRE)–VenatoRx Pharmaceuticals today announced that it was named one of the “2019 Best Places to Work” in the Greater Philadelphia area by the Philadelphia Business Journal.
Nabriva Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Aug. 06, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that Chief Commercial Officer Francesco Maria Lavino will provide a company overview and business update at the 2019 Wedbush PacGrow...
Iterum Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference
DUBLIN, Ireland and CHICAGO, Aug. 01, 2019 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced its participation at the Canaccord Genuity...
Summit Therapeutics to Present at the Canaccord Genuity Growth Conference
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Present at the Canaccord Genuity Growth Conference Oxford, UK, and Cambridge, MA, US, 1 August 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces that Mr Glyn Edwards, Chief Executive Officer, will present at the Canaccord Genuity...
SCYNEXIS, Inc. to Present at the 39th Annual Canaccord Genuity Global Growth Conference
JERSEY CITY, N.J., July 31, 2019 /PRNewswire/ — SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the 39th Annual Canaccord Genuity Global Growth Conference at The InterContinental Boston on Wednesday, August 7, 2019 at 5:00 p.m. ET. A live webcast...
Paratek Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 6, 2019
BOSTON, July 29, 2019 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced the Company will host a conference call and live audio webcast on Tuesday, August 6, 2019 at 4:30 p.m. EDT to report its financial results for the quarter...
Cidara Therapeutics Reports Positive Topline Results In Phase 2 STRIVE B Trial of Antifungal Rezafungin
SAN DIEGO, July 29, 2019 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives, including immunotherapies, today reported positive topline results from Part B of the global Phase 2 STRIVE trial evaluating the company’s lead antifungal candidate rezafungin.